BNP Blood Tests Can Detect Heart Damage From Chemotherapy During Cancer Treatment
Serial BNP measurements during doxorubicin chemotherapy detected early cardiac damage in lymphoma patients before clinical symptoms appeared, potentially enabling early intervention.
Quick Facts
What This Study Found
Serial BNP measurements detected doxorubicin-induced cardiotoxicity before clinical symptoms or echocardiographic changes in 30 lymphoma patients, with BNP rising progressively with cumulative drug exposure.
Key Numbers
How They Did This
Prospective cohort study in 30 non-Hodgkin's lymphoma patients receiving CHOP chemotherapy. Serial ANP, BNP, and echocardiography performed throughout treatment up to cumulative doxorubicin doses of 400-500 mg/m².
Why This Research Matters
Doxorubicin is one of the most effective cancer drugs but causes irreversible heart damage. A simple blood test that detects early cardiac injury could allow dose adjustments before permanent damage occurs, saving both hearts and lives.
The Bigger Picture
Cardio-oncology — protecting the heart during cancer treatment — is a growing medical field. BNP monitoring during chemotherapy represents a practical, inexpensive approach to preventing treatment-related heart failure.
What This Study Doesn't Tell Us
30 patients — moderate sample. ANP was less useful. Specific BNP cutoff values for clinical decision-making were not established. Not all types of cardiotoxicity may be detected by BNP.
Questions This Raises
- ?Should BNP monitoring be standard during anthracycline chemotherapy?
- ?What BNP cutoff should trigger dose reduction?
- ?Can early intervention based on BNP prevent irreversible cardiotoxicity?
Trust & Context
- Key Stat:
- Early detection BNP rose before echocardiographic changes or symptoms appeared, providing a window for intervention during doxorubicin chemotherapy
- Evidence Grade:
- Moderate evidence from a prospective cohort study with serial measurements in a clinically relevant population, limited by moderate sample size.
- Study Age:
- Published in 1999. Cardiac biomarker monitoring during chemotherapy has become increasingly standard, with troponin and BNP/NT-proBNP both used clinically.
- Original Title:
- Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma.
- Published In:
- European journal of haematology, 62(2), 135-41 (1999)
- Authors:
- Nousiainen, T, Jantunen, E, Vanninen, E, Remes, J, Vuolteenaho, O, Hartikainen, J
- Database ID:
- RPEP-00546
Evidence Hierarchy
Frequently Asked Questions
Can chemotherapy damage the heart?
Yes, doxorubicin and similar chemotherapy drugs can cause permanent heart muscle damage. The risk increases with cumulative doses, and the damage was historically only detected when symptoms appeared — often too late.
How does BNP testing help?
BNP rises when the heart is stressed. Monitoring it during chemotherapy can catch heart damage early, allowing doctors to adjust treatment before irreversible injury occurs — potentially saving both the patient's heart and their cancer treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00546APA
Nousiainen, T; Jantunen, E; Vanninen, E; Remes, J; Vuolteenaho, O; Hartikainen, J. (1999). Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma.. European journal of haematology, 62(2), 135-41.
MLA
Nousiainen, T, et al. "Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma.." European journal of haematology, 1999.
RethinkPeptides
RethinkPeptides Research Database. "Natriuretic peptides as markers of cardiotoxicity during dox..." RPEP-00546. Retrieved from https://rethinkpeptides.com/research/nousiainen-1999-natriuretic-peptides-as-markers
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.